Optimization of continuous infusion of piperacillin-tazobactam in children with fever and neutropenia

Pediatric Infectious Disease Journal

Volumn 32, Issue 9, 2013, Pages 962-964

  Delvallée, Melanie ^a   Mazingue, Françoise ^a,b   Abouchahla, Wadi ^a,b   Delebarre, Mathilde ^a,b   Wallet, Frédéric ^a   Courcol, René ^a   Kipnis, Eric ^a,b   Dessein, Rodrigue ^a  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Continuous infusion; Fever neutropenia; Pharmacokinetic and pharmacodynamic optimization; Piperacillin tazobactarn

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM;

ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; BOLUS INJECTION; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; STEADY STATE;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; FEMALE; FEVER OF UNKNOWN ORIGIN; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEUTROPENIA; PENICILLANIC ACID; PIPERACILLIN; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

EID: 85047688243     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318298dfb8     Document Type: Article

References (23)

1. Paganini HR, Aguirre C, Puppa G, et al.; Febrile Neutropenia Study Group. A prospective, multicentric scoring system to predict mortality in febrile neutropenic children with cancer. Cancer. 2007;109:2572-2579.
2. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52:e56-e93.
3. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1-10; quiz 11.
4. Ariano RE, Nyhlen A, Donnelly JP, et al. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother. 2005;39:32-38.
5. Buijk SL, Gyssens IC, Mouton JW, et al. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother. 2002;49:121-128.
6. Mouton JW, Vinks AA, Punt NC. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother. 1997;41:733-738.
7. Jaruratanasirikul S, Sriwiriyajan S, Ingviya N. Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia. J Pharm Pharmacol. 2002;54:1693-1696.
8. Kuti JL, Nightingale CH, Quintiliani R, et al. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagn Microbiol Infect Dis. 2002;44:51-57.
9. Theuretzbacher U. Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer. Clin Infect Dis. 2012;54:1785-1792.
10. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998;27:10-22.
11. Bergeron MG, Simard P. Influence of three modes of administration on the penetration of latamoxef into interstitial fluid and fibrin clots and its in-vivo activity against Haemophilus influenzae. J Antimicrob Chemother. 1986;17:775-784.
12. Bakker-Woudenberg IA, Van Den Berg JC, Fontijne P, et al. Efficacy of continuous versus intermittent administration of penicillin G in Streptococcus pneumoniae pneumonia in normal and immunodeficient rats. Eur J Clin Microbiol. 1984;3:131-135.
13. Craig WA, Ebert SC. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother. 1992;36:2577-2583.
14. Roosendaal R, Bakker-Woudenberg IA, Van Den Berg JC, et al. Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats. J Infect Dis. 1985;152:373-378.
15. Egerer G, Goldschmidt H, Salwender H, et al. Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after highdose chemotherapy and peripheral blood stem cell transplantation. Int J Antimicrob Agents. 2000;15:119-123.
16. Leder K, Turnidge JD, Korman TM, et al. The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis. J Antimicrob Chemother. 1999;43:113-118.
17. Rappaz I, Decosterd LA, Bille J, et al. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Eur J Pediatr. 2000;159:919-925.
18. Vinks AA, Brimicombe RW, Heijerman HG, et al. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J Antimicrob Chemother. 1997;40:125-133.
19. Blondiaux N, Wallet F, Favory R, et al. Daily serum piperacillin monitoring is advisable in critically ill patients. Int J Antimicrob Agents. 2010;35:500-503.
20. Leon Shargel A B C Y, Susanna W-P Applied Biopharmaceutics and Pharmacokinetics. 6th ed. New York: McGraw-Hill Medical; 2012.
21. Reed MD, Goldfarb J, Yamashita TS, et al. Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children. Antimicrob Agents Chemother. 1994;38:2817-2826.
22. Courter JD, Kuti JL, Girotto JE, et al. Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population. Pediatr Blood Cancer. 2009;53:379-385.
23. Tamma PD, Jenh AM, Milstone AM. Prolonged β-lactam infusion for Gram-negative Infections. Pediatr Infect Dis J. 2011;30:336-337.